Abstract Body

Background: HCV infection generally progresses to chronic infection, but a minority of individuals can spontaneously clear the infection. CD4 T cells are critical for the spontaneous control of HCV but the mechanisms of protection and immune failure remain to be elucidated, especially in HIV+ individuals who generally have higher rate of chronic viremia. Methodology: We longitudinally analyzed the immunophenotype of early HCV-specific CD4 T cell responses in 45 genotype-1 HCV- infected individuals with well-defined clinical outcomes, including 6 patients with a pre-existing HIV-1 infection. HCV-specific CD4 T cells were studied directly ex vivo using a panel of HCV- MHC class II tetramers, and analyzed for their expressions of various immune makers in multicolor flow cytometry. All statistical analyses were performed with the Spearman correlation test. Results: HCV-specific CD4 T cells were initially detectable directly ex vivo by MHC class II tetramers in15/15 (100%) resolvers and 16/24 (67%) progressors with mono-HCV infection, as well as in 6/6 (100%) HIV+ individuals, including one who spontaneously cleared HCV. HCV-specific CD4 T cells disappeared from most progressors within 13-41 weeks after onset of infection, while these cells persisted in patients with resolving infection. Early HCVspecific CD4 T cells were mostly comprised of activated effector memory cells expressing high levels of PD-1, CTLA-4, and CD95, and low levels of CD127, irrespective of infection outcomes and HIV status. Interestingly, CD38, PD-1, CTLA-4, and CD95 were quickly downregulated with resolution of infection. Furthermore, decreased expressions of CD38 (p<0.0001), PD-1 (p <0.0001), and CTLA-4 (p<0.0001) were associated with increased expression of CD127 on HCV-specific CD4 T cells. In contrast, in persisting infection HCV-specific CD4 T cells continued to express high levels of CD38, PD-1, CTLA-4, and CD95, and failed to upregulate CD127 before disappearing from blood. Finally, HCV-specific CD4 T cells in resolving infection predominantly expressed CCR4 while expressing intermediate levels of CXCR3 and low levels of CCR6, CXCR5, and Foxp3. In contrast, there was a trend towards more Foxp3, CXCR5, and CXCR3 and fewer CCR4 expressing HCV-specific CD4 T cells in persisting infection. Conclusions: Both HIV+ and HIV- patients generate HCV-specific CD4 T cell responses with a uniform phenotype in the early phase of acute infection, indicating that priming of response does not explain infection outcomes. However, with persistent viremia, HCV-specific CD4 T cells quickly display the phenotypes, resembling those of exhausted and dysfunctional T cells, irrespective of HIV-1 status. These changes may contribute to viral persistence and the rapid disappearance of HCV-specific CD4 T cells.